Phathom Pharmaceuticals/$PHAT
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Primary listing
Employees
371
Headquarters
Website
PHAT Metrics
BasicAdvanced
$695m
-
-$1.27
0.49
-
Price and volume
Market cap
$695m
Beta
0.49
52-week high
$18.31
52-week low
$8.03
Average daily volume
1.4m
Financial strength
Current ratio
1.924
Quick ratio
1.82
Long term debt to equity
-149.321
Total debt to equity
-160.345
Interest coverage (TTM)
-0.64%
Profitability
EBITDA (TTM)
-40.134
Gross margin (TTM)
82.92%
Net profit margin (TTM)
-41.34%
Operating margin (TTM)
-16.96%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
-8.80%
Return on equity (TTM)
26.42%
Valuation
Price to revenue (TTM)
2.857
Price to book
-2.04
Price to tangible book (TTM)
-2.04
Price to free cash flow (TTM)
-18.552
Free cash flow yield (TTM)
-5.39%
Free cash flow per share (TTM)
-0.472
Growth
Revenue change (TTM)
110.16%
Earnings per share change (TTM)
-73.14%
3-year earnings per share growth (CAGR)
-33.60%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
PHAT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.